Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients (eDetect-mCRC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05068531
Recruitment Status : Not yet recruiting
First Posted : October 6, 2021
Last Update Posted : October 6, 2021
Sponsor:
Collaborators:
Exactis Innovation
Chaire Roger Des Groseillers d'oncologie chirurgicale HBP de l'Université de Montréal
Canexia Health
Information provided by (Responsible Party):
Centre hospitalier de l'Université de Montréal (CHUM)

Brief Summary:
In North America, colorectal cancer patients with resectable liver-restricted metastases (mCRC-LR) are treated with approximately 6 months of preoperative systemic multi-agent chemotherapy. Actuarial data however supports that approximately 20% of mCRC-LR patients can be cured without as much systemic chemotherapy. Prospective phase II-III trials also support that awaiting recurrence to initiate further metastases-targeted or systemic treatment may provide patients with longer overall survival while avoiding toxicities in those without recurrence.

Condition or disease
Colorectal Cancer Metastatic

Detailed Description:

The general objective of this single-centre, prospective observational cohort study in 100 mCRC-LR patients treated with curative intent along standard of care (SOC), is to obtain real-world data on administered therapies, selected complications, and oncological outcomes, while longitudinally collecting biospecimens to enable correlative research investigating early biological markers of treatment resistance and recurrence.

Cryopreservation of sequential blood derivatives, tumor tissue, and stool samples will allow investigation of circulating tumor DNA (ctDNA), T-cell receptor repertoire, somatic cancer mutations, immune and other gene expression, gut microbiome, and soluble factors.

The first biological marker that will be investigated in correlative research will be longitudinal measurements of ctDNA targeting 30 oncogenes, 23 axons, and 146 hotspots (Follow It assay, Canexia Health). Additional biological markers will be defined in subsequent amendments to this protocol.

The results are expected to provide important insights for the design of future trials investigating ways to personalize therapy, such as to: a) avoid the unnecessary use of neoadjuvant or adjuvant systemic chemotherapy, b) avoid morbid hepatectomies in patients unlikely to benefit, c) test novel preoperative therapies in patients more likely to benefit, and d) modulate the intensity of follow-up.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Observational Cohort Study for Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients Undergoing Systemic Chemotherapy and Liver Resection With Curative Intent
Estimated Study Start Date : October 2021
Estimated Primary Completion Date : October 2026
Estimated Study Completion Date : October 2026

Group/Cohort
Observational
We plan to recruit up to 100 mCRC patients with baseline resectable liver-restricted metastases (mCRC-LR) without evidence of extra-hepatic metastases, with primary tumor already or to be resected (metachronous or synchronous disease), planned to receive upfront FOLFOX-based preoperative neoadjuvant systemic chemotherapy, who achieved no-evidence of disease (NED) in the abdomen by standard imaging.



Primary Outcome Measures :
  1. Radiological response to pre-operative chemotherapy as assessed by RECIST v1.1 [ Time Frame: Approximately three months ]
  2. Biochemical response to pre-operative chemotherapy as assessed by plasmatic CEA measurement, change from baseline after 4 cycles of chemotherapy [ Time Frame: Approximately three months ]
  3. Pathological response to pre-operative chemotherapy as assessed by Ryan and Rubbia Brandt Tumor Regression Grade (TRG) scores on resected tumors [ Time Frame: Approximately three months ]
  4. Tumor response to pre-operative chemotherapy as assessed by change in circulating tumor DNA level, change from baseline [ Time Frame: Approximately three months ]
    Follow It assay, Canexia Health

  5. Histopathologic growth pattern as assessed by percent replacement, desmoplastic, and pushing features measured at the interface of liver metastasis and non tumoral liver [ Time Frame: Three to four months ]
  6. Post-operative minimal residual disease as assessed by circulating tumor DNA detection after tumor resection with curative intent [ Time Frame: Approximately 1 months after resection with curative intent ]
    Follow It assay, Canexia Health

  7. Time to radiological recurrence after tumor resection with curative intent [ Time Frame: Up to three years after tumor resection with curative intent ]
  8. Time to biochemical recurrence as assessed by plasmatic CEA measurement, level above the upper limit occurring after tumor resection with curative intent [ Time Frame: Up to three years after tumor resection with curative intent ]
  9. Time to tumor recurrence as assessed by detection or change in level of circulating tumor DNA after tumor resection with curative intent [ Time Frame: Up to three years after tumor resection with curative intent ]
    Follow It assay, Canexia Health


Secondary Outcome Measures :
  1. Incidence and grade of FOLFOX-induced neuropathy, as assessed by Sensory Subscale of the NCI CTCAE scale, version 3 [ Time Frame: Two to three months pre-operatively and during post-operative adjuvant chemotherapy ]
  2. Incidence of allergic reaction to oxaliplatin diagnosed by treating physicians and requiring desensitization or change in chemotherapy regimen [ Time Frame: Two to three months pre-operatively and during post-operative adjuvant chemotherapy ]
  3. Incidence of hospitalization for febrile neutropenia diagnosed by treating physicians [ Time Frame: Two to three months pre-operatively and during post-operative adjuvant chemotherapy ]
  4. Ninety-day post-surgical complications, defined by Clavien Dindo grading system [ Time Frame: 90 days after tumor resection ]
  5. Disease-specific survival after complete tumor resection [ Time Frame: Up to three years after tumor resection with curative intent ]

Biospecimen Retention:   Samples With DNA
  • Serial blood samples processed to obtain plasma for ctDNA and soluble factor research, buffy coat for genomic research, and mononuclear cells for live cells immune assays;
  • Tumor samples processed to allow genomic, proteomic and live cell research;
  • Adjacent non-tumoral tissue to allow genomic, proteomic and live cell research;
  • Stool samples at baseline and post neoadjuvant chemotherapy to allow metagenomics research.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
100 mCRC patients with baseline resectable liver-restricted metastases (mCRC-LR) without evidence of extra-hepatic metastases, with primary tumor already or to be resected (metachronous or synchronous disease), planned to receive upfront FOLFOX-based preoperative neoadjuvant systemic chemotherapy, who achieved no-evidence of disease (NED) in the abdomen by standard imaging.
Criteria

Inclusion Criteria:

  1. Male or female patients (≥18 years of age at the time of consent);
  2. Stage IV colon or rectal adenocarcinoma with liver-restricted metastasis(es) for whom partial hepatectomy with curative intent is planned;
  3. Instead of, or in addition to, partial hepatectomy, liver metastases may be ablated by needle radio frequency or microwave; in case of a solitary liver metastasis, three core-needle biopsies are provided for research at time of the procedure and prior to tissue destruction;
  4. Patients may undergo planned two-stage partial hepatectomies;
  5. Patients may have at baseline lung micro nodules or intra-abdominal enlarged nodes or nodules of unknown nature, not considered as extra-hepatic metastases in the opinion of the investigator;
  6. Patients who are scheduled to receive FOLFOX-based pre-hepatectomy may receive any additional combined agents, such as and not limited to Irinotecan, anti-EGFR, and anti-VEGF drugs;
  7. Patients are willing and able to provide serial blood samples, tumor and adjacent tissues, and stool samples for research;
  8. The timing and specific treatments of the primary colon or rectal tumor is per SOC, at the discretion of the treating physician, including the use of pre-operative radiotherapy for rectal cancer;
  9. Patients may receive post-operative adjuvant chemotherapy per SOC, at the discretion of the treating physician;
  10. Patients must consent to the Exactis Personalized my Treatment registry.

Exclusion Criteria:

  1. Pregnant or breastfeeding patients,
  2. Hereditary colorectal cancer (e.g., familial colonic polyposis or Lynch syndrome), and
  3. Presence of concurrent other cancer(s).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05068531


Contacts
Layout table for location contacts
Contact: Wiam Belkaid, PhD 514-890-8000 ext 23242 wiam.belkaid.chum@ssss.gouv.qc.ca

Locations
Layout table for location information
Canada, Quebec
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2X 3E4
Contact: Wiam Belkaid, PhD    514-836-3273 ext 23242    wiam.belkaid.chum@ssss.gouv.qc.ca   
Principal Investigator: Simon Turcotte, MD,MSc         
Sponsors and Collaborators
Centre hospitalier de l'Université de Montréal (CHUM)
Exactis Innovation
Chaire Roger Des Groseillers d'oncologie chirurgicale HBP de l'Université de Montréal
Canexia Health
Investigators
Layout table for investigator information
Principal Investigator: Simon Turcotte, MD, MSc CHUM
Layout table for additonal information
Responsible Party: Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov Identifier: NCT05068531    
Other Study ID Numbers: 21.103
First Posted: October 6, 2021    Key Record Dates
Last Update Posted: October 6, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM):
Real world data
Observational study
Circulating tumor DNA
Microbiome
Tumor immunology
Metastatic colorectal cancer
Liver metastasis
Biomarker
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases